This report evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseases as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.
At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukaemia and one for haemophilia. A search was conducted for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bi-specifics).
Of the 110 clinical stage bispecific antibodies, 50% is used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for the treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology.
The traditional application of bispecifics for targeting two tumour-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).
The report highlights the use of bispecific antibody technology for the generation of:
The report includes a compilation of currently active projects in research and development of bispecific therapeutic antibodies in cancer and non-cancer indications.
Competitor projects are listed in a tabular format providing information on:
Drug Codes
Target / Mechanism of Action
Class of Compound
Company
Product Category
Indication
R&D Stage and additional comments with a hyperlink leading to the source of information
The "Global Immunoprecipitation Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.
The Global Immunoprecipitation Testing Market size is estimated...
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...
Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its...
Susan G. Komen®, the world's leading breast cancer organization commends the State Assembly's proposed funding increase of $2.5 million for the Cancer Services Program (CSP) in the FY2025 Budget....
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night. Now, a new study proposes a mechanism that determines which memories are...
While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which...